GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's rob ...

These 10 stocks could mint the next wave of millionaires › IDEAYA Biosciences (NASDAQ:IDYA), a precision oncology company focused on developing targeted therapies for cancer, reported its ...

IDEAYA Biosciences' clinical trial progress, strong financials, and diversified pipeline signal long-term growth potential ...

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 ...

Deal with DoveTree, established by Harvard professor Gregory Verdine, adds to growing list of licensing tie-ups with Chinese ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

On July 25, Leads Biolabs made its official debut on the Hong Kong Stock Exchange. Its shares surged as much as 117% intraday ...

In July 2025, Clinuvel Inc. conducted a CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in ...